0001654954-24-001965.txt : 20240220 0001654954-24-001965.hdr.sgml : 20240220 20240220161051 ACCESSION NUMBER: 0001654954-24-001965 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20240216 FILED AS OF DATE: 20240220 DATE AS OF CHANGE: 20240220 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: tsai chung-jung CENTRAL INDEX KEY: 0001859356 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41461 FILM NUMBER: 24653368 MAIL ADDRESS: STREET 1: 8880 RIO SAN DIEGO DRIVE STREET 2: SUITE 800 CITY: SAN DIEGO STATE: CA ZIP: 92108 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Ainos, Inc. CENTRAL INDEX KEY: 0001014763 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 751974352 STATE OF INCORPORATION: TX FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: AINOS, INC. STREET 2: 8880 RIO SAN DIEGO DRIVE SUITE 800 CITY: SAN DIEGO STATE: CA ZIP: 92108 BUSINESS PHONE: 858-869-2986 MAIL ADDRESS: STREET 1: AINOS, INC. STREET 2: 8880 RIO SAN DIEGO DRIVE SUITE 800 CITY: SAN DIEGO STATE: CA ZIP: 92108 FORMER COMPANY: FORMER CONFORMED NAME: AMARILLO BIOSCIENCES INC DATE OF NAME CHANGE: 19960516 4 1 section16.xml PRIMARY DOCUMENT X0508 4 2024-02-16 0001014763 Ainos, Inc. AIMD 0001859356 tsai chung-jung 8880RIOSANDIEGODRIVE, SUITE800 SANDIEGO CA 92108 true false CommonStock 2024-02-16 4 A false 16200 0.8693 A 72186 D RSU 2024-02-16 4 C false 16200 D CommonStock 16200 111400 D Reference is made to (i)540,000 RSUs that were granted on August 15, 2013, adjusted to 108,000 shares giving effect to the 1 for 5 reverse share split on December 14, 2023, pursuant to the Company's 2023 Stock Incentive Plan, with vesting occurringin increments of 15% on 2/15/24, 15% on 8/15/24,30% on 8/15/25, and 40% on 8/15/26 subject to normal and customary termination events; and (ii) 70,000 RSUs granted under the 2021 Stock Incentive Plan, as amended by the 2023 Stock Incentive Plan, adjusted to 14,000 shares giving effect to the 1 for 5 reverse share split on December 14, 2023, with vesting occurring in increments of 2,100 shares on 5/14/23 and 11/14/23, respectively, 4,200shares on 11/14/24 and 5,600 shares on 11/14/25, subject to normal and customary termination events. /s/ Chun-Hsien Tsai POA for Chun-Jung Tsai 2024-02-20 EX-24 2 ex24_poa.htm POWER OF ATTORNEY ex24_poa
 
Exhibit 24
LIMITED POWER OF ATTORNEY
 
The undersigned hereby constitutes and appoints Chun-Hsien Tsai, and with full power of substitution, the undersigned’s true and lawful attorney-in-fact to:
 
(1)           execute for and on behalf of the undersigned, in the undersigned’s capacity as officer, director and/or shareholder of Ainos, Inc. (the “Company”), from time to time the following U.S. Securities and Exchange Commission (“SEC”) forms: (i) Form ID, including any attached documents, to effect the assignment of codes to the undersigned to be used in the transmission of information to the SEC using the EDGAR System; (ii) Form 3, Initial Statement of Beneficial Ownership of Securities, including any attached documents;  (iii) Form 4, Statement of Changes in Beneficial Ownership of Securities, including any attached documents; (iv) Form 5, Annual Statement of Beneficial Ownership of Securities in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended, and the rules thereunder, including any attached documents; (v) Schedule 13D and (vi) amendments of each thereof, in accordance with the Securities Exchange Act of 1934, as amended, and the rules thereunder, including any attached documents;
 
(2)           do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form 3, 4 or 5, Schedule 13D or any amendment(s) thereto, and timely file such form(s) with the SEC and any securities exchange, national association or similar authority; and
 
(3)           take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact’s discretion.
 
The undersigned hereby grants to each such attorney-in-fact, acting singly, full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact’s substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.  The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned’s responsibilities to comply with Section 16 or Regulation 13D-G of the Securities Exchange Act of 1934, as amended.  The undersigned hereby agrees to indemnify the attorneys-in-fact and the Company from and against any demand, damage, loss, cost or expense arising from any false or misleading information provided by the undersigned to the attorneys-in-fact.
 
This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file such forms with respect to the undersigned’s holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.  This Power of Attorney supersedes any prior power of attorney in connection with the undersigned’s capacity as an officer and/or director of the Company.  This Power of Attorney shall expire as to any individual attorney-in-fact if such attorney-in-fact ceases to be an executive officer of, or legal counsel to, the Company.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of January 16, 2024.
 

/s/ Chun-Jung Tsai
Name: Chun-Jung Tsai